• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CF1
Click for more information
10.0% 2.2¢

COMPLII FINTECH SOLUTIONS LTD - Charts / Financials

Market Cap $12.58M  ! watchlist Created with Sketch. Add to my watchlist
Technology Software - Application

Complii FinTech Solutions Limited provides end-to-end compliance and risk management... Complii FinTech Solutions Limited provides end-to-end compliance and risk management software as a service (SaaS) platform for equity capital markets participants, from dealers / brokers, financial advisers, financial planners, wealth advisers, to listed and unlisted companies and investors. The Company has five segments: Complii segment, a financial technology platform sector; the PrimaryMarkets segment, a trading platform sector; the Advisor Solutions Group segment, an Australian Financial Service Licence (AFSL) sector; the Registry Direct segment, a share register sector, and the MIntegrity segment, a compliance consulting sector. Its products and services include registry services from inception of a corporation or trust, trading facilities whilst unlisted (pre-IPO), new capital raising (pre-IPO rounds + IPO listing + placements post listing), administration tools and shareholder services plus all the compliance controls required for those AFSL holders and their registered users.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 11.24am 04/10/2024 (20 minute delay) ?
Day
Open 2.1¢   Day High 2.2¢   Day Low 2.1¢
Daily Volume 360666
Bids   Sellers
Number Price Volume   Number Price Volume
1 2.2¢ 103090   1 2.3¢ 300000

Directors & Senior Management

Mr. Craig Mason Executive Chairman of the Board
Mr. Tim Thornton Interim Chief Executive Officer
Ms. Karla Mallon Chief Financial Officer
Mr. Charles Blake Chief Marketing and Technology Officer
Ms. Alison Sarich Managing Director, Director
Mr. Herbert Gavin Solomon Executive Director
Ms. Sharon Wright Global Head - Operations
Ms. Karen Logan Company Secretary
Mr. Ian Steuart Roe Director
Mr. Greg Gaunt Non-Executive Director
Mr. Nicholas Prosser Non-Executive Director

Data source: Refinitiv

(20min delay)
Last
2.2¢ 		Change
0.002(10.0%) 		Mkt cap ! $12.58M
Open High Low Value Volume
2.1¢ 2.2¢ 2.1¢ $7.78K 360.6K

Buyers (Bids)

No. Vol. Price($)
1 103090 2.2¢
 

Sellers (Offers)

Price($) Vol. No.
2.3¢ 300000 1
View Market Depth
Last trade - 15.54pm 04/10/2024 (20 minute delay) ?
Last
2.1¢ 		  Change
0.002 ( 5.00 %)
Open High Low Volume
2.1¢ 2.1¢ 2.1¢ 89200
Last updated 11.24am 04/10/2024 ?

Top Stories

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Solstice Minerals (ASX:SLS) shares were up nearly 2.5% in afternoon trades on Friday as it announced drilling plans at Yarri.
Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation After just over a week, the thrill China’s latest stimulus announcements put into world markets has started to subside.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.